Sr. Associate Scientist/Principal Scientist, Upstream Process Development
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth.
Codiak BioSciences is seeking an upstream biochemical engineer to help develop the company’s novel cell culture bioprocessing platforms for exosome therapeutics. Responsibilities will include, but will not be limited to, assisting in fed-batch and perfusion process development and design of experiments to drive process understanding, process scale up and characterization at various scales, determination of critical process parameters, and developing process control strategies. The Sr./Princ. Associate Scientist will be responsible for generating exosome harvest material to support internal research activities as well as non-GLP and GLP nonclinical studies. (S)he will assist in technology transfer to CMOs and in the preparation of CMC documentation for regulatory and/or patent filings. The ability to apply innovative, critical thinking and technical knowledge to analyze experimental results and communicate clearly to functional line management regarding progress against technical objectives/milestones is required. Work in a team setting and interaction with other research and development groups will be expected.
- This position requires a solid understanding and fluency in the engineering concepts that underlie these methodological approaches. The successful candidate will have excellent organization and communication skills, the ability to collaborate effectively, and an enthusiasm for problem solving. As part of a growing start-up company, the incumbent will be uniquely exposed to a broad range of activities both inside and outside of the laboratory.
- • Mammalian cell culture
- • Familiarity with ambr, bench-top and pilot scale bioreactor systems
- • Experience in process development and scale up/ down
- • Familiarity with bioanalytics and/or cell-based assays
- Additional prior experience in any of the following areas will be an advantage:
- • Process transfer to Manufacturing
- • Understanding of exosome biology
- • Cell line engineering
- Education: BSc or MSc in Chemical Engineering, Biochemical Engineering, or an equivalent engineering/science degree with 5–8 years of experience working in the industry.
Compensation & Benefits
Codiak provides competitive compensation and benefits package that support and reward the contributions of each member of the team.
Apply TodayThose interested in joining the team effort at Codiak BioSciences to advance the nascent and exciting field of exosome technology into therapeutics with transformative potential are invited to email their CV.
Recent discoveries have demonstrated that exosomes derived from normal cells can act as a potent and safe delivery system for multiple therapeutic payloads. These small vesicles, which leave cells and travel throughout the body, can mediate dramatic effects in animal models of disease.
We are developing a broad platform for the delivery of macromolecules to the cytoplasm of diverse cells and tissues, to create a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need. The company’s technology exploits the natural propensity of exosomes to transmit macromolecule payloads between cells to create a pipeline of drugs across a broad range of diseases, including those associated with currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas.
We are now producing drug candidate exosomes using the engExTM platform, our novel therapeutic engine for exosomes. We tailor exosomes to express molecules on their surfaces and/or deliver specific cargo inside. This affords us the flexibility for designing proprietary drug candidates; exosomes can be mixed and matched into rational and targeted combinations with the potential for a broad therapeutic platform.
As of December 2017, Codiak has raised a combined $168.5M in Series A-C financing. The company maintains partnerships with academic exosome labs and has multiple paths to clinical and commercial success through the breadth of the company’s research, strength of its IP position and proprietary innovation behind its production capabilities.
Codiak’s CEO and first employee Doug Williams, Ph.D., (former EVP of Biogen R&D, CEO of ZymoGenetics) espouses the belief that inspired employees create great science. Employees treat the company as if it was their own and report that there is “direct and respectful communication,” and “trust that teammates will do the right thing and never compromise integrity.”
Named one of 11 disruptive startups “on a do-or-die mission to launch new meds” by Endpoints News in January 2018, Codiak is in the heart of Boston’s biotechnology hub at 500 Technology Square in Cambridge, Massachusetts.
Codiak BioSciences is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.